Appendix 1: Clinical Trials Analyzed Study Drug(s) Target Biomarkers/ Subtype Combination Sponsor 1. Sustaining Prolif- erative Signaling PI3/Akt/mTOR BKM120 PI3 TripleNegative SOLTI Breast Cancer Research Group BKM120 PI3 HER2- BKM120/paclitaxel vs. BKM120/placebo Novartis BKM120 PI3 Hormone+_HER2- Fulvestrant Novartis BKM120 PI3 Hormone+_HER2- Fulvestrant Novartis BKM120 PI3 All Capecitabine  Novartis BKM120, olaparib PI3K TripleNegative Dana-Farber/Harvard Cancer Center GDC-0032 PI3 Hormone+ Fulvestrant Genentech GDC-0032 PI3 HER2- Docetaxel or pacli- taxel Genentech Active, not recruiting GDC-0941 PI3 Hormone+_HER2- Paclitaxel Genentech GDC-0941 P13 TripleNegative Cisplatin Vanderbilt-Ingram Cancer Center BAY80-6946 PI3 All Paclitaxel Bayer AZD8186 PI3 TripleNegative AstraZeneca Suspended as of 8/1 Triciribine Akt HER2- Cahaba Trametinib, GSK2141795 Akt TripleNegative National Cancer Institute BYL719 PI3 Hormone+_HER2- Letrozole Vanderbilt-Ingram Cancer Center BYL719, AMG479 PI3K, IGF1, and IGF2 Hormone+ Novartis, Amgen BYL719, BGJ398 PI3 All Novartis BYL719 PI3 Hormone+ Letrozole or exemes- tane Sloan Kettering BYL719 PI3 N/A Paclitaxel Novartis LDE225, BKM120 PI3K, Hedge- hog All Novartis LY3023414 PI3/mTOR All Eli Lilly PF-05212384 PI3/mTOR All Docetaxel (ER+), cis- platin (triple negative), dacomitinib (HER2+) Pfizer AZD2014 mTOR Hormone+ Fulvestrant AstraZeneca MGAH22 mTOR HER2- MacroGenics Everolimus mTOR HER2+ Lapatinib University of Kansas Everolimus mTOR Hormone+_HER2- Letrozole Novartis Everolimus mTOR Hormone+_HER2- Trastuzumab Emory University Everolimus mTOR Hormone+_HER2- Fulvestrant Eastern Cooperative Oncology Group (ECOG) Everolimus/exemestane mTOR Hormone+ Compared to everolimus alone or capecitabine  Novartis Everolimus/fulvestrant or everolimus/fulves- trant/anastrozole mTOR Hormone+ Compared to fulves- trant alone SWOG collaboration with Novartis and AstraZeneca Everolimus/letrozole/ lapatinib mTOR Hormone+_HER2- University of Maryland CC-223  mTOR All Celgene  Unknown as of 8/1 Sirolimus (rapamycin) mTOR HER2+ Hercpetin Yale Cancer Center